Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents

Described here is the development of gadolinium(III) texaphyrin-platinum(IV) conjugates capable of overcoming platinum resistance by 1) localizing to solid tumors, 2) promoting enhanced cancer cell uptake, and 3) reactivating p53 in platinum-resistant models. Side by side comparative studies of thes...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2020-03, Vol.117 (13), p.7021-7029
Hauptverfasser:	Thiabaud, Grégory, He, Guangan, Sen, Sajal, Shelton, Kathryn A, Baze, Wallace B, Segura, Luke, Alaniz, Julie, Munoz Macias, Ruben, Lyness, Greg, Watts, Alan B, Kim, Hyun Min, Lee, Hyunseung, Cho, Mi Young, Hong, Kwan Soo, Finch, Rick, Siddik, Zahid H, Arambula, Jonathan F, Sessler, Jonathan L
Format:	Artikel
Sprache:	eng
Schlagworte:	A549 Cells Animal models Animals Anticancer properties Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antitumor activity Antitumor agents Biological Sciences Cell culture Chemical compounds Comparative studies Conjugates Dosage Drug Resistance, Neoplasm Drugs FDA approval Female Gadolinium HCT116 Cells Humans In vivo methods and tests Localization Metalloporphyrins - administration & dosage Metalloporphyrins - pharmacokinetics Mice, Nude Oxaliplatin Oxaliplatin - administration & dosage Oxaliplatin - pharmacokinetics p53 Protein Physical Sciences Platinum Prodrugs Prodrugs - administration & dosage Prodrugs - pharmacokinetics Redox properties Regulatory agencies Solid tumors Tissue Distribution Tumor Suppressor Protein p53 - metabolism Tumors Xenograft Model Antitumor Assays Xenografts Xenotransplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!